Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of Graz
Previous small studies and clinical cases have suggested a possible association between pulmonary hypertension (PH) and chronic myeloproliferative disorders (CMPD). MPD may cause PH through different mechanisms as: high cardiac output, asplenia, direct obstruction of pulmonary arteries by megakaryocytes, chronic thromboembolic endothelial pulmonary hypertension (CTEPH), porto-pulmonary hypertension (POPH). However, the exact prevalence of PH in this group of disorders is not known.
This study is designed to identify the pulmonary vascular changes and describe the prevalence of pulmonary hypertension (defined in this study as mean pulmonary arterial hypertension (mPAP) ≥25mmHg as assessed by right-heart catheterization (RHC) or systolic pulmonary arterial pressure (sPAP) ≥37mmHg (2.9 m/s) assessed by echocardiography.
Age
18–95
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with myeloproliferative disorders
Written informed consent
You may not be if
Manifest pulmonary hypertension
Significant pulmonary disease
Left-sided heart failure or diastolic compliance dysfunction